Uveal melanoma (UM) is a primary neoplasm of the eye arising from the melanocytes residing in the iris, ciliary body or choroid. It is the most frequent intraocular malignancy and often determines metastases at distant sites, with a peculiar tropism for the liver. Metastatic UM has a poor prognosis, as any treatment affects the natural course of this fatal disease. Herein, we report a case of a UM metastatic to the liver in a 54 year-old female patient, initially treated with nivolumab without success. The patient was then scheduled for selective internal radiation therapy (SIRT) while continuing immunotherapy. This combination led to a complete and durable response and the patient is currently free of disease, two years after the diagnosis of the hepatic metastases. The association between SIRT and immunotherapy (IT) has very promising perspectives for metastatic UM, especially considering the disappointing or contradictory results of classic chemotherapies, IT alone and targeted therapies. Furthermore, this combination has been shown to have a good security profile. However, further studies are needed to confirm the efficacy of associating SIRT and IT and to clarify some unsolved problems, such as the timing of administration of these two therapies.

Long-term maintained response to selective internal radiation therapy in an oligometastatic uveal melanoma patient treated with concomitant Anti-PD-1 therapy / Proietti, Ilaria; Skroza, Nevena; Filippi, Luca; Bernardini, Nicoletta; Mambrin, Alessandra; Tolino, Ersilia; Rossi, Giovanna; Marchesiello, Anna; Marraffa, Federica; Volpe, Salvatore; Bagni, Oreste; Potenza, Concetta. - In: LIFE. - ISSN 2075-1729. - 11:7(2021). [10.3390/life11070692]

Long-term maintained response to selective internal radiation therapy in an oligometastatic uveal melanoma patient treated with concomitant Anti-PD-1 therapy

Proietti, Ilaria;Skroza, Nevena;Bernardini, Nicoletta;Mambrin, Alessandra;Tolino, Ersilia;Marchesiello, Anna;Marraffa, Federica;Volpe, Salvatore;Potenza, Concetta
Conceptualization
2021

Abstract

Uveal melanoma (UM) is a primary neoplasm of the eye arising from the melanocytes residing in the iris, ciliary body or choroid. It is the most frequent intraocular malignancy and often determines metastases at distant sites, with a peculiar tropism for the liver. Metastatic UM has a poor prognosis, as any treatment affects the natural course of this fatal disease. Herein, we report a case of a UM metastatic to the liver in a 54 year-old female patient, initially treated with nivolumab without success. The patient was then scheduled for selective internal radiation therapy (SIRT) while continuing immunotherapy. This combination led to a complete and durable response and the patient is currently free of disease, two years after the diagnosis of the hepatic metastases. The association between SIRT and immunotherapy (IT) has very promising perspectives for metastatic UM, especially considering the disappointing or contradictory results of classic chemotherapies, IT alone and targeted therapies. Furthermore, this combination has been shown to have a good security profile. However, further studies are needed to confirm the efficacy of associating SIRT and IT and to clarify some unsolved problems, such as the timing of administration of these two therapies.
2021
uveal melanoma; selective internal radiation therapy; immunotherapy; anti-PD1
01 Pubblicazione su rivista::01i Case report
Long-term maintained response to selective internal radiation therapy in an oligometastatic uveal melanoma patient treated with concomitant Anti-PD-1 therapy / Proietti, Ilaria; Skroza, Nevena; Filippi, Luca; Bernardini, Nicoletta; Mambrin, Alessandra; Tolino, Ersilia; Rossi, Giovanna; Marchesiello, Anna; Marraffa, Federica; Volpe, Salvatore; Bagni, Oreste; Potenza, Concetta. - In: LIFE. - ISSN 2075-1729. - 11:7(2021). [10.3390/life11070692]
File allegati a questo prodotto
File Dimensione Formato  
Proietti_Long-term-maintained_2021.pdf

accesso aperto

Note: https://www.mdpi.com/2075-1729/11/7/692
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 666.53 kB
Formato Adobe PDF
666.53 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1570174
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 0
social impact